Allspring Global Investments Holdings LLC Grows Position in Gossamer Bio, Inc. (NASDAQ:GOSS)

Allspring Global Investments Holdings LLC raised its holdings in Gossamer Bio, Inc. (NASDAQ:GOSSGet Rating) by 37.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 37,239 shares of the company’s stock after acquiring an additional 10,129 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Gossamer Bio were worth $446,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Quantbot Technologies LP boosted its stake in Gossamer Bio by 11.3% during the first quarter. Quantbot Technologies LP now owns 13,801 shares of the company’s stock worth $119,000 after buying an additional 1,401 shares during the last quarter. Virtus ETF Advisers LLC boosted its position in shares of Gossamer Bio by 15.5% during the 2nd quarter. Virtus ETF Advisers LLC now owns 17,370 shares of the company’s stock valued at $145,000 after acquiring an additional 2,331 shares during the last quarter. Invesco Ltd. grew its holdings in shares of Gossamer Bio by 5.8% in the first quarter. Invesco Ltd. now owns 49,769 shares of the company’s stock valued at $432,000 after purchasing an additional 2,732 shares during the period. Jane Street Group LLC increased its position in Gossamer Bio by 13.3% during the first quarter. Jane Street Group LLC now owns 31,691 shares of the company’s stock worth $275,000 after purchasing an additional 3,726 shares during the last quarter. Finally, Point72 Hong Kong Ltd purchased a new position in Gossamer Bio during the first quarter worth about $33,000. 90.18% of the stock is currently owned by institutional investors and hedge funds.

Gossamer Bio Trading Up 5.5 %

GOSS opened at $2.10 on Tuesday. The business has a fifty day moving average price of $4.21 and a 200 day moving average price of $9.44. The company has a debt-to-equity ratio of 3.73, a current ratio of 5.93 and a quick ratio of 5.93. Gossamer Bio, Inc. has a 12 month low of $1.57 and a 12 month high of $15.20. The stock has a market capitalization of $198.40 million, a price-to-earnings ratio of -0.73 and a beta of 1.12.

Gossamer Bio (NASDAQ:GOSSGet Rating) last announced its quarterly earnings data on Thursday, November 3rd. The company reported ($0.65) EPS for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.01. Sell-side analysts expect that Gossamer Bio, Inc. will post -2.75 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on GOSS. SVB Leerink decreased their price objective on Gossamer Bio from $15.00 to $10.00 and set an “outperform” rating on the stock in a report on Wednesday, December 7th. Raymond James reduced their price objective on shares of Gossamer Bio from $18.00 to $15.00 and set an “outperform” rating on the stock in a report on Thursday, November 17th. The Goldman Sachs Group lowered their target price on shares of Gossamer Bio from $22.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, December 7th. UBS Group reduced their price target on shares of Gossamer Bio from $19.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, December 7th. Finally, Bank of America lowered their price objective on shares of Gossamer Bio from $15.00 to $7.00 in a research report on Wednesday, December 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $10.25.

Gossamer Bio Profile

(Get Rating)

Gossamer Bio, Inc engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions.

Featured Articles

Institutional Ownership by Quarter for Gossamer Bio (NASDAQ:GOSS)

Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.